Tackling influenza with broadly neutralizing antibodies.
- Corti D Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.
- Cameroni E Humabs BioMed SA, 6500 Bellinzona, Switzerland.
- Guarino B Humabs BioMed SA, 6500 Bellinzona, Switzerland.
- Kallewaard NL Department of Infectious Disease, MedImmune, Gaithersburg, MD 20878, USA.
- Zhu Q Department of Infectious Disease, MedImmune, Gaithersburg, MD 20878, USA.
- Lanzavecchia A Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
- 2017-05-22
Published in:
- Current opinion in virology. - 2017
Animals
Antibodies, Monoclonal
Antibodies, Neutralizing
Antiviral Agents
Hemagglutinin Glycoproteins, Influenza Virus
Humans
Influenza A virus
Influenza B virus
Influenza, Human
Mice
Orthomyxoviridae Infections
English
Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last decade, new methods have allowed the efficient interrogation of the human antibody repertoire from influenza immune individuals and the isolation of several monoclonal antibodies capable of dealing with the high variability of influenza viruses. Here, we will provide a comprehensive overview of the specificity, antiviral and immunological mechanisms of action and development into the clinic of broadly reactive monoclonal antibodies against influenza A and B viruses.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1016/j.coviro.2017.03.002
- PMID 28527859
- Persistent URL
- https://sonar.ch/global/documents/292149
Statistics
Document views: 59
File downloads:
- Full-text: 0